TPMT
Basic information
Region (hg38): 6:18128311-18155077
Links
Phenotypes
GenCC
Source:
Clinical Genomic Database
Source:
| Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
|---|---|---|---|---|---|
| Thiopurine S-methyltransferase deficiency | AR | Pharmacogenomic | Dose adjustment/selection of specific medications (eg, azathioprine, cisplatin, mercaptopurine, s-adenoslymethionine, thioguanine) may be indicated in order to avoid severe toxicity | Biochemical | 2758725; 1960624; 7862671; 8644731; 9177237; 11304783; 15228163; 16220112; 19898482 |
ClinVar
This is a list of variants' phenotypes submitted to
- not_specified (16 variants)
- Thiopurine_S-methyltransferase_deficiency (6 variants)
- Thiopurine_response (4 variants)
- not_provided (3 variants)
- TPMT-related_disorder (2 variants)
- Azathioprine_response (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the TPMT gene is commonly pathogenic or not. These statistics are base on transcript: NM_000000367.5. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 4 | |||||
| missense | 22 | 23 | ||||
| nonsense | 1 | |||||
| start loss | 0 | |||||
| frameshift | 1 | |||||
| splice donor/acceptor (+/-2bp) | 2 | |||||
| Total | 0 | 0 | 27 | 4 | 0 |
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| TPMT | protein_coding | protein_coding | ENST00000309983 | 8 | 26764 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 0.00000711 | 0.740 | 125645 | 0 | 103 | 125748 | 0.000410 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | 0.290 | 120 | 129 | 0.928 | 0.00000646 | 1618 |
| Missense in Polyphen | 27 | 31.177 | 0.86602 | 410 | ||
| Synonymous | 0.894 | 36 | 43.5 | 0.828 | 0.00000231 | 433 |
| Loss of Function | 1.15 | 10 | 14.8 | 0.678 | 6.24e-7 | 181 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.000358 | 0.000358 |
| Ashkenazi Jewish | 0.00 | 0.00 |
| East Asian | 0.000109 | 0.000109 |
| Finnish | 0.00120 | 0.00120 |
| European (Non-Finnish) | 0.000493 | 0.000492 |
| Middle Eastern | 0.000109 | 0.000109 |
| South Asian | 0.000327 | 0.000327 |
| Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Catalyzes the S-methylation of thiopurine drugs such as 6-mercaptopurine (also called mercaptopurine, 6-MP or its brand name Purinethol) and 6-thioguanine (also called tioguanine or 6- TG) using S-adenosyl-L-methionine as the methyl donor (PubMed:657528, PubMed:18484748). TPMT activity modulates the cytotoxic effects of thiopurine prodrugs. A natural substrate for this enzyme has yet to be identified. {ECO:0000269|PubMed:18484748, ECO:0000269|PubMed:657528, ECO:0000305}.;
- Pathway
- Drug metabolism - other enzymes - Homo sapiens (human);Thiopurine Pathway, Pharmacokinetics/Pharmacodynamics;Mercaptopurine Action Pathway;Azathioprine Action Pathway;Thioguanine Action Pathway;Mercaptopurine Metabolism Pathway;Metapathway biotransformation Phase I and II;Methylation Pathways;Methylation;Phase II - Conjugation of compounds;Biological oxidations;Metabolism
(Consensus)
Recessive Scores
- pRec
- 0.166
Intolerance Scores
- loftool
- 0.703
- rvis_EVS
- 0.79
- rvis_percentile_EVS
- 87.4
Haploinsufficiency Scores
- pHI
- 0.0952
- hipred
- N
- hipred_score
- 0.170
- ghis
- 0.402
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.129
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Tpmt
- Phenotype
- mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; growth/size/body region phenotype; homeostasis/metabolism phenotype;
Gene ontology
- Biological process
- nucleobase-containing compound metabolic process;drug metabolic process;methylation
- Cellular component
- cytosol
- Molecular function
- thiopurine S-methyltransferase activity;S-adenosyl-L-methionine binding